{"id":"W4403303574","doi":"10.1111/pcmr.13205","title":"Meeting Report From the 2023 Cure Ocular Melanoma (<scp>CURE OM</scp>) Global Science Meeting, Philadelphia, <scp>PA</scp>, November 2023","year":2024,"lang":"en","type":"article","venue":"Pigment Cell & Melanoma Research","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Patient Safety Institute","funders":"EMD Serono; Genentech; Plexxikon; Astellas Pharma; Eisai; Castle Biosciences; G1 Therapeutics; Ascentage Pharma; Pfizer; Moderna; Incyte; BeiGene; Melanoma Research Foundation; GlaxoSmithKline; Tizona Therapeutics; AstraZeneca; Novocure; Mereo BioPharma; Celldex Therapeutics; Daiichi Sankyo Europe; Foghorn Therapeutics; Gilead Sciences; Regeneron Pharmaceuticals; Melanoma Research Alliance; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; NGM Biopharmaceuticals; Exelixis; Sanofi","keywords":"Medicine; Melanoma; Gerontology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006865676,0.0007254891,0.0008471612,0.0004460095,0.00151023,0.0005700855,0.001320844,0.0005868173,0.0003705182],"category_scores_gemma":[0.002313374,0.0005221532,0.000480989,0.003209982,0.001381299,0.0003889385,0.001302157,0.001993828,0.003268858],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00132754,"about_ca_system_score_gemma":0.001884852,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002069412,"about_ca_topic_score_gemma":0.0003026662,"domain_scores_codex":[0.9894596,0.0007329048,0.001046676,0.002249611,0.004131434,0.002379718],"domain_scores_gemma":[0.9935986,0.002621193,0.0002785022,0.001919897,0.0007164073,0.0008653938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001147809,0.002636299,0.4425768,0.0007601211,0.00231967,0.04429821,0.00307941,0.00008764389,0.04326162,0.001099837,0.4563604,0.003405224],"study_design_scores_gemma":[0.004519121,0.001659395,0.09673124,0.00173177,0.001168716,0.001607119,0.005408272,0.002165212,0.06311837,0.002054848,0.8194676,0.000368344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8040159,0.03058736,0.00004543057,0.005589045,0.001629359,0.00200386,0.0002219133,0.000253658,0.1556535],"genre_scores_gemma":[0.9618569,0.001229571,0.0009578636,0.0003646536,0.001811838,0.000359347,0.0004329448,0.0001310201,0.03285584],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3631072,"threshold_uncertainty_score":0.9997897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04097590354583888,"score_gpt":0.358749423360031,"score_spread":0.3177735198141921,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}